News

Fierce Pharma13h
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
Why Novo Nordisk Stock Popped Today
Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...
'We Don’t Know What is Being Alleged': Ozempic Defendants Argue Plaintiffs' Master Complaint is Too Vague
During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
FDA stops sale of generic versions of Ozempic and Wegovy: What to do if you’re taking them
Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...
Futurism on MSN4d
Novo Nordisk Is Getting Absolutely Destroyed
Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.
Novo Remade Denmark. Then Came the Stock Selloff.
Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...